BeStock  
Stocks › Biotechnology › ODTX

Odyssey Therapeutics ODTX

US equityMarket cap rank #3291Biotechnology
$16.96 −$1.38 (-7.52%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $16.96 0.00%
Open$17.65
Prev close$18.34
Day range$16.46 – $18.08
Volume677.8K
Market cap$815.23M
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00-100.0% YoY
Operating profit-$53.36M-46.7% YoY
Net profit-$53.06M-49.6% YoY
Diluted EPS-$1.10-46.3% YoY
Free cash flow-$42.05M-34.3% YoY
Operating cash flow-$41.54M

Revenue, last 8 quarters

$1.8MDec '24$1.9MMar '25$959.0KJun '25$99.0KSep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-35.9MDec '24$-38.4MMar '25$-41.2MJun '25$-35.5MSep '25$-33.5MDec '25$-38.3MMar '26$-52.8MJun '26$-53.1MSep '26

Diluted EPS by quarter

-1.34Dec '24-1.39Mar '25-1.50Jun '25-0.75Sep '25-0.71Dec '25-0.81Mar '26-1.74Jun '26-1.10Sep '26

Free cash flow by quarter

$-34.6MDec '24$-39.5MMar '25$-34.3MJun '25$-31.3MSep '25$-25.6MDec '25$-41.2MMar '26$-34.7MJun '26$-42.0MSep '26

Annual revenue

$0.0FY22$1.0MFY23$4.5MFY24$3.0MFY25

Profitability & balance sheet

Return on equity-47.3%
Return on assets-40.5%
Return on invested capital-47.1%
Current ratio12.94
Liabilities / assets14.2%
Cash & investments$326.00M
Total debt$17.95M
Net cash (debt)$308.06M

Income statement

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Revenue as Reported $0.00 $0.00 $0.00 $2.98M $0.00
Total Operating Revenue $0.00 $0.00 $0.00 $2.98M $0.00
Operating Expense $53.36M $46.74M $39.67M $164.13M $37.48M
Selling and Admin Expenses $11.24M $10.51M $7.35M $37.52M $6.19M
-General & Admin Expense $11.24M $10.51M $7.35M $37.52M $6.19M
Research & Development $42.12M $36.23M $32.32M $126.62M $31.29M
Operating Profit -$53.36M -$46.74M -$39.67M -$161.16M -$37.48M
Net Non-Operating Interest Income (Expense) $3.85M $2.81M $1.70M $6.33M $2.11M
Non-Operating Interest Income $3.86M $2.83M $1.71M $6.35M $2.12M
Non-Operating Interest Expense $12,000.00 $20,000.00 $10,000.00 $17,000.00 $12,000.00
Other Income (Expense) -$3.50M -$8.87M -$226,000.00 $5.25M $813,000.00
Special Income (Charges) -$3.31M -$8.73M -$109,000.00 $4.05M -$295,000.00
-Less:Restructuring and Mergern & Acquisition $3.31M $8.73M $109,000.00 -$4.05M $295,000.00
Other Non-Operating Income (Expenses) -$194,000.00 -$138,000.00 -$117,000.00 $1.20M $1.11M
Pretax Profit -$53.01M -$52.80M -$38.20M -$149.57M -$34.56M
Tax $49,000.00 -$8,000.00 $63,000.00 -$927,000.00 -$1.04M
Net Profit -$53.06M -$52.79M -$38.26M -$148.65M -$33.52M
Profit from Continuing Operations -$53.06M -$52.79M -$38.26M -$148.65M -$33.52M
Net Income to Parent Company -$53.06M -$52.79M -$38.26M -$148.65M -$33.52M
Net Income to Common Stockholders -$53.06M -$52.79M -$38.26M -$148.65M -$33.52M
Basic EPS -$1.10 -$1.74 -$0.81 -$5.39 -$0.71
Diluted EPS -$1.10 -$1.74 -$0.81 -$5.39 -$0.71

Balance sheet

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Total Assets $438.10M $483.85M $229.07M $269.79M $269.79M
Total Current Assets $337.80M $321.46M $185.10M $190.66M $190.66M
Cash and Cash Equivalents & Short-Term Investments $326.00M $310.58M $175.75M $181.36M $181.36M
-Cash and Cash Equivalents $80.64M $82.03M $35.72M $41.69M $41.69M
-Short Term Investments $245.36M $228.54M $140.03M $139.67M $139.67M
Other Current Assets $11.80M $10.89M $9.35M $9.30M $9.30M
Total Non-Current Assets $100.30M $162.39M $43.97M $79.13M $79.13M
Net PPE $20.76M $21.92M $24.48M $26.01M $26.01M
-Gross PPE $34.63M $34.95M $39.58M $40.17M $40.17M
-Accumulated Depreciation -$13.86M -$13.04M -$15.11M -$14.16M -$14.16M
Investments and Advances $60.99M $122.49M $0.00 $35.20M $35.20M
-Available for Sale Securities $60.99M $122.49M – $35.20M $35.20M
Goodwill and Other Intangible Assets $14.12M $14.19M $14.23M $14.59M $14.59M
-Goodwill $14.12M $14.10M $14.07M $14.33M $14.33M
Other Non-Current Assets $4.43M $3.79M $5.26M $3.33M $3.33M
Total Liabilities $62.33M $62.63M $752.76M $758.07M $758.07M
Total Current Liabilities $26.10M $28.30M $22.21M $26.48M $26.48M
Payables $8.26M $7.67M $8.22M $7.87M $7.87M
-Accounts Payable $8.26M $7.67M $8.22M $7.87M $7.87M
Current Accrued Expenses $6.53M $8.16M $4.42M $6.25M $6.25M
Short-Term Debt and Capital Lease Obligation $5.53M $5.47M $5.37M $5.21M $5.21M
-Current Capital Lease Obligation $5.53M $5.47M $5.37M $5.21M $5.21M
Current Deferred Liabilities $20,000.00 $3.17M $1.45M $64,000.00 $64,000.00
Other Current Liabilities $839,000.00 $492,000.00 $399,000.00 $374,000.00 $374,000.00
Total Non-Current Liabilities $36.23M $34.33M $730.55M $731.59M $731.59M
Long Term Debt and Capital Lease Obligation $17.95M $19.36M $20.75M $21.90M $21.90M
-Long Term Capital Lease Obligation $17.95M $19.36M $20.75M $21.90M $21.90M
Convertible preferred securities $0.00 $0.00 $703.56M $703.56M $703.56M
Other Non-Current Liabilities $18.28M $14.97M $6.24M $6.13M $6.13M
Total Equity $375.77M $421.22M -$523.69M -$488.28M -$488.28M
Stockholders' Equity $375.77M $421.22M -$523.69M -$488.28M -$488.28M
Capital Stock $5,000.00 $5,000.00 $0.00 $0.00 $0.00
-Common Stock $5,000.00 $5,000.00 $0.00 $0.00 $0.00
Additional Paid-In Capital $1.09B $1.08B $82.85M $79.62M $79.62M
Retained Earnings -$712.25M -$659.19M -$606.40M -$568.14M -$568.14M
Gains/Losses Not Affecting Retained Earnings -$985,000.00 -$505,000.00 -$147,000.00 $245,000.00 $245,000.00
-Other Intangible Assets – $86,000.00 $160,000.00 $262,000.00 $262,000.00

Cash flow

Line item 2026 Q3 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q4
Operating Cash Flow -$41.54M -$34.51M -$41.04M -$129.47M -$25.33M
Net cash flow from continuing operations -$41.54M -$34.51M -$41.04M -$129.47M -$25.33M
Net Income from Continuing Operations -$53.06M -$52.79M -$38.26M -$148.65M -$33.52M
Gain/Loss from Continuing Operations -$4,000.00 $639,000.00 -$33,000.00 $1.36M $201,000.00
Depreciation & Depletion & Amortization $1.01M $1.04M $1.17M $4.91M $1.16M
Other Non-Cash Items $4.21M $9.68M $988,000.00 -$606,000.00 $1.43M
Change in Working Capital -$1.98M $1.17M -$7.19M -$4.73M $3.31M
-Change in Prepaid Assets -$907,000.00 -$1.59M $3,000.00 -$3.21M -$2.08M
-Change in Payables and Accrued Expense $865,000.00 $2.55M -$4.28M -$2.09M $6.87M
-Change in Other Current Assets -$637,000.00 $1.47M -$1.69M $5.16M $105,000.00
-Change in Other Current Liabilities -$1.30M -$1.26M -$1.23M -$4.60M -$1.58M
Net cash flow from investing $43.29M -$211.44M $34.80M -$103.94M $11.53M
Net Cash Flow from Continuing Investing Activities $43.29M -$211.44M $34.80M -$103.94M $11.53M
Net PPE Purchase and Sale -$483,000.00 $95,000.00 -$148,000.00 -$875,000.00 -$228,000.00
Net Investment Purchase and Sale $43.78M -$211.54M $34.95M -$103.07M $11.75M
Financing Cash Flow -$3.18M $292.16M $484,000.00 $215.65M $5.94M
Net Cash Flow from Continuing Financing Activities -$3.18M $292.16M $484,000.00 $215.65M $5.94M
Net Issuance Payments Of Debt -$47,000.00 -$46,000.00 -$24,000.00 – –
Net Common Stock Issuance -$3.28M – – – –
Net Preferred Stock Issuance $0.00 – – $212.46M $2.98M
Proceeds from Stock Option Exercised $152,000.00 $586,000.00 $651,000.00 $3.19M $2.86M
Ending Cash Balance $84.09M $85.48M $39.17M $44.90M $44.90M
Net Change in Cash -$1.43M $46.21M -$5.75M -$17.77M -$7.86M
Beginning Cash Balance $85.48M $39.17M $44.90M $62.35M $52.73M
Effect of Exchange Rate Changes $38,000.00 $104,000.00 $24,000.00 $316,000.00 $25,000.00
Free Cash Flow -$42.05M -$34.69M -$41.18M -$130.70M -$25.56M
Net Other Financing Charges – – -$143,000.00 – –

Discussion

No comments yet — be the first to weigh in on ODTX.

Sign in to join the discussion.

Scroll to Top